Menu
Not yet recruiting NCT07251101

Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery

No phase Interventional Anesthesia, Intravenous Hemodynamic Stability Gynecologic Surgery

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Remimazolam, Propofol.
Who it may be relevant to
Registry conditions: Anesthesia, Intravenous, Hemodynamic Stability, Gynecologic Surgery. Basic parameters: up to 65 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Randomized, Parallel, Open-label With Blinded Assessment Study Comparing Hemodynamic Profiles Between Remimazolam- and Propofol-based Total Intravenous Anesthesia in Patients Undergoing Robot-assisted Gynecologic Surgery

Overview

This single-center study at CHA Ilsan Medical Center compares intraoperative hemodynamics between remimazolam- and propofol-based total intravenous anesthesia (TIVA) in patients undergoing robot-assisted gynecologic surgery requiring pneumoperitoneum and steep Trendelenburg positioning.

Detailed description

This study aims to compare intraoperative hemodynamic characteristics between remimazolam- and propofol-based total intravenous anesthesia (TIVA) in patients undergoing robot-assisted gynecologic surgery. Continuous invasive blood pressure will be analyzed to evaluate time-weighted average (TWA) and area-under-the-curve (AUC) differences between groups. The study is designed as a randomized, parallel, open-label with blinded assessment trial.

Interventions

  • Drug Remimazolam
    Induction with remimazolam 6 mg·kg-¹·h-¹ with remifentanil Ce 4 ng·mL-¹ (Minto model); maintenance remimazolam 1-2 mg·kg-¹·h-¹, titrated (±0.2) to maintain PSI 25-50 and hemodynamic targets. Standard care otherwise per protocol.
  • Drug Propofol
    Induction with propofol Ce 4 ng·mL-¹ with remifentanil Ce 4 ng·mL-¹; maintenance propofol Ce 2.5-3.5 ng·mL-¹, titrated (±0.2) to maintain PSI 25-50 and hemodynamic targets. Standard care otherwise per protocol.

Primary outcome measures

  • MAP (Time-Weighted Average) [Time frame: from induction start (first anesthetic administration) to operating room exit (transfer from OR), approximately up to 5 hours per participant.]
Secondary outcome measures (2)
  • Area Under the Curve (AUC) for Hypertensive Burden [Time frame: from anesthesia induction to operating room exit, assessed continuously during surgery (approximately 2 to 5 hours per participant).]
  • Area Under the Curve (AUC) for Hypotensive Burden [Time frame: from anesthesia induction to operating room exit, assessed continuously during surgery (approximately 2 to 5 hours per participant).]

Eligibility criteria

Inclusion criteria

  • Female patients <65 years of age
  • American Society of Anesthesiologists (ASA) physical status I-II
  • Scheduled to undergo robotic hysterectomy under general anesthesia

Exclusion criteria

  • Body mass index (BMI) > 35 kg/m²
  • Baseline hypotension (systolic blood pressure <100 mmHg) or bradycardia (heart rate <60 bpm)
  • History of ischemic heart disease or cardiac conduction block
  • Significant cardiopulmonary disease, including hypoxemia (SpO₂ <90%), uncontrolled asthma, or chronic obstructive pulmonary disease (COPD)
  • Use of inhalational anesthetics during anesthesia
  • Conversion from robotic/laparoscopic surgery to open laparotomy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Supportive care

Study locations

South Korea · 2 centers
  • CHA Ilsan Medical Center — Goyang-si
  • CHA Ilsan Medical Center — Goyang-si

Publications

  • Lee JM, Lee J, Kang SH, Jung K, Yeo H, Lee JY, Joo Y. Comparison of intraoperative hemodynamic parameters between propofol- and remimazolam-based total intravenous anesthesia in patients undergoing robotic gynecologic surgery: a randomized controlled trial protocol. Front Pharmacol. 2026 Jul 20;17:1775804. doi: 10.3389/fphar.2026.1775804. eCollection 2026. PMID 42544348

Identifiers

NCT: NCT07251101 · ICHA 2025-07-005

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗